Charou, Despoina
Rogdakis, Thanasis
Latorrata, Alessia
Valcarcel, Maria
Papadogiannis, Vasileios
Athanasiou, Christina
Tsengenes, Alexandros
Papadopoulou, Maria Anna
Lypitkas, Dimitrios
Lavigne, Matthieu D.
Katsila, Theodora
Wade, Rebecca C.
Cader, M. Zameel
Calogeropoulou, Theodora
Gravanis, Achille
Charalampopoulos, Ioannis http://orcid.org/0000-0003-3415-7332
Funding for this research was provided by:
Horizon 2020 (765704)
HORIZON EUROPE European Innovation Council (101099145)
IFET S.A.
Article History
Received: 1 February 2024
Accepted: 26 June 2024
First Online: 6 July 2024
Declarations
:
: All primary cells derived from animals that were grouped housed in the Animal House of the Institute of Molecular Biology and Biotechnology (IMBB-FoRTH, Heraklion, Greece), in a temperature-controlled facility on a 12-h light/dark cycle, fed by standard chow diet and water ad libitum. For cell isolation, mice were deeply anesthetized with ketamine/xylazine and euthanatized via decapitation. All research activities strictly adhered to the EU adopted Directive 2010/63/EU on the protection of animals used for scientific purposes. All procedures were performed under the approval of Veterinary Directorate of Prefecture of Heraklion (Crete) and carried out in compliance with Greek Government guidelines and the guidelines of FORTH ethics committee and were performed in accordance with approved protocols from the Federation of European Laboratory Animal Science Associations (FELASA) and Use of Laboratory animals [License number: EL91-BIOexp-02), Approval Code/Protocol Number: 360667, Approval Date: 29/11/2021 (active for 3 years). Title of the approved project: “Investigating the effects of neurotrophins and their synthetic analogues on the mechanisms of neurodegeneration and neurogenesis in Alzheimer’s disease and the effect of neuroimplants based on porous collagen scaffolds in the central nervous system trauma.” Human iPS cell lines were kindly provided by Dr Cader. The human iPSC lines used for this study were derived from human skin biopsy fibroblasts and blood erythroblasts, following signed informed consent, with approval from the UK NHS Research Ethics Committee (REC: 13/SC/0179 and 10/H0505/71) and were derived as part of the IMI-EU sponsored StemBANCC consortium.No human subjects were involved in the study, thus there was not any need for consent to participate.
: Not applicable.
: The authors declare no competing interests.